Wednesday, February 19, 2025

#Niger - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

Backyard poultry in Niamey Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6259

____

Tuesday, February 18, 2025

#Neuraminidase #reassortment and #oseltamivir #resistance in clade 2.3.4.4b A(#H5N1) viruses circulating among #Canadian #poultry, 2024

Abstract

We report the detection of a clade 2.3.4.4b A(H5N1) reassortant virus with a neuraminidase surface protein derived from a North American lineage low-pathogenic avian influenza virus. This virus caused a widespread and ongoing outbreak across 45 poultry farms in British Columbia, Canada. Isolates from 8 farms reveal a mutation in the neuraminidase protein (H275Y) that is exceptionally rare among clade 2.3.4.4b viruses (present in 0.045% of publicly available clade 2.3.4.4b isolates). NA-H275Y is a well-known marker of resistance to the neuraminidase inhibitor oseltamivir. We demonstrate that this substitution maintains its resistance phenotype on the genetic background of H5N1 clade 2.3.4.4b viruses.

Source: Emerging Microbes and Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2469643

____

Two additional Avian #Influenza #H9N2 #Human Cases in #China (HK CHP)

 {Excerpt}

{Avian Influenza H9N2 Human Cases in China}

-- Mainland China: 2 cases (0 death) 

- Avian influenza A(H9N2): 

* Guangdong Province

- A 72-year-old woman with onset on December 26, 2024. 

- A 56-year-old woman with onset on January 20, 2025. 

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/files/pdf/2025_avian_influenza_report_vol21_wk07.pdf

____

#Argentina - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

National Service of Agri-Food Health and Quality (SENASA) received a notification concerning a high mortality of birds and signs consistent with high pathogenicity avian influenza (HPAI) in a backyard. The suspicion was immediately addressed and samples were taken for analysis. The samples tested positive for HPAI H5. The affected species are chickens, ducks and turkeys. The affected premises are adjacent to a body of water, so contact with wild birds is presumed. Stamping out, sanitary burial, cleaning and disinfection of all the birds in the premises will be carried out. We will update the quantitative data in subsequent follow-up reports.

Source: WOAH, https://wahis.woah.org/#/in-review/6272

_____

#Cambodia - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

Avian influenza was found in sick and dead wild birds along the shores of a lake in a bird sanctuary.

Location: Theay commune, Ba Phnum district, Prey Veng province.

Source: WOAH, https://wahis.woah.org/#/in-review/6273

____

#Canada - High pathogenicity avian #influenza #H5N5 viruses (#poultry) (Inf. with) - Immediate notification

On January 24, 2025, the Canadian Food Inspection Agency (CFIA) was notified of mortality in a non-commercial backyard layer poultry farm in Newfoundland and Labrador. The CFIA National Centre for Foreign Animal Disease has confirmed on February 12, 2025 that the virus was H5N5. The HA of the H5 virus from the samples belongs to Eurasian Gs/GD lineage HPAI H5N1 (2.3.4.4b) with cleavage site motif of “PLREKRRKR/GLF”, compatible with HPAI viruses. The sample contained AI virus similar to European like - H5N5 (2023) viruses which came to Canada via the Atlantic flyway. The viruses contained wholly Eurasian H5N5 genome segments. The CFIA has immediately quarantined the IP and is implementing strict movement controls and a stamping out policy. Primary control zone (PCZ) has been put in place around the IP. Surveillance is ongoing in the affected areas. WOAH data on poultry and non-poultry can be visualized and extracted on the AI dashboard in domestic birds available at https://cahss.ca/cahss-networks/poultry-new (select poultry categories to show data related to HPAI poultry events 4294, 5229, 6003, and 6267). Wildlife surveillance as well as the Canadian Notifiable Avian Influenza Surveillance System (CanNAISS) activities for poultry are ongoing in Canada.

Source: WOAH, https://wahis.woah.org/#/in-review/6267

____

#TĂ¼rkiye (Rep. of) - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

A total of 390 birds belonging to various individual backyard owners in a village. The birds included various species such as chickens, geese, and ducks. There are no commercial poultry operations within the village or the surrounding 10km surveillance zone.

In Hatay Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6270

____

North #American-Origin #Influenza A (#H10) viruses in Eurasian Wild #Birds (2022–2024): Implications for the Emergence of Human #H10N5 Virus

Abstract

During our surveillance of avian influenza viruses (AIVs) in wild birds across China, H10Nx viruses were isolated from diverse migratory flyways between 2022 and 2024. We identified one wild-bird H10N5 strain that shared a common ancestor with the human H10N5 virus in multiple gene segments. Phylogenetic and molecular dating revealed the origin and evolution of H10N5, highlighting the need for continued monitoring.

Source: Emerging Microbes and Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2465308

____

#Bosnia and #Herzegovina - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

Four Mute Swans in Federacija Bosna i Hercegovina. 

Source: WOAH, https://wahis.woah.org/#/in-review/6275?reportId=172294&fromPage=event-dashboard-url

_____

Monday, February 17, 2025

Combing the haystacks: The #search for highly pathogenic avian #influenza virus using a combined #clinical and research-developed #testing strategy

Abstract

Background

Highly pathogenic H5 avian influenza A has caused sporadic human infections, increasing the risk for potential human–to–human spread. In 2024, the U.S. experienced outbreaks among poultry and cattle, prompting enhanced surveillance

Objective

To evaluate an H5 testing algorithm in subjects with respiratory symptoms presenting for routine care during low influenza A virus circulation. 

Design

Observational study using clinical– and research–developed nucleic acid amplification tests (NAATs) and pooled screening methods. 

Setting

Academic medical center in Boston, MA. 

Participants

5,400 symptomatic individuals contributing 6,935 respiratory specimens from June 23 to August 28, 2024. 

Measurements

Specimens underwent initial respiratory pathogen testing per clinical protocols, which did not routinely include influenza due to low summer–month prevalence. Influenza A–positive specimens were subtyped using a clinical assay for H5 assessment. SARS–CoV–2–negative specimens not tested for influenza were screened in pooled batches. Positive pools were deconvoluted to individual specimens and screened for H5 using quantitative polymerase chain reaction. 

Results

Influenza A was detected in 40 of 6,935 specimens (0.6%), comprising 35 of 5,400 unique subjects (0.7%). No H5 infections were identified. Of the 35 influenza–positive individuals, 10 cases (29%) were found through research–specific screening of SARS–CoV–2–negative specimens. No deaths attributed to influenza were recorded. 

Limitations

Single center design, convenience sampling, absence of ocular specimens, and minimal sampling in high–risk areas may limit generalizability. 

Conclusion

Expanded influenza testing using pooled NAATs successfully identified low–prevalence influenza A and ruled out H5 in this cohort. These data support targeted influenza screening to enhance surveillance for emerging subtypes rather than a broad–based clinical testing strategy for influenza A testing.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2025.02.12.25321810v1

_____

A two-step #mechanism for RIG-I #activation by #influenza virus mini viral #RNAs

Abstract

Influenza A virus (IAV) non-canonical replication products can be bound by host pathogen sensors, such as retinoic acid-inducible gene I (RIG-I). However, innate immune activation is infrequent in cell culture infection, in particular by adapted strains. Moreover, it is not understood why non-canonical IAV RNAs activate RIG-I in a sequence- or RNA structure-dependent manner. We therefore hypothesized that multiple errors need to occur before influenza virus RNA synthesis activates innate immune signaling. To test this idea, we investigated whether RIG-I activation is stimulated by the non-canonical or aberrant transcription of mini viral RNAs (mvRNA), a <125 nt long RNA that is overexpressed in pandemic and highly pathogenic IAV infections. Using mvRNA sequences identified in tissue culture and ferret infections, we find that mvRNAs can cause non-canonical transcription termination through a truncated 5ʹ polyadenylation signal or a 5ʹ transient RNA structure that interrupts polyadenylation. The resulting capped complementary RNAs (ccRNA) can stimulate the release of a template mvRNA in vitro. Finally, we find that both mvRNA and ccRNA sequences can be bound by RIG-I in cell culture and that blocking mvRNA transcription with baloxavir reduces IFN promoter activity. Overall, our findings indicate that sequential rounds of non-canonical or aberrant viral replication and transcription are needed before mvRNAs trigger innate immune signaling in a sequence-dependent manner.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.01.04.630666v2

_____

Sunday, February 16, 2025

The Adoration of the Magi, William Morris (1890)

 


Public Domain.

Source: WikiArt, https://www.wikiart.org/en/william-morris/the-adoration-of-the-magi-1890

_____

#Coronavirus Disease Research #References (by AMEDEO, Feb. 16 '25)

 


    Am J Obstet Gynecol

  1. DOMGUE JF, Chandra M, Yu R, Shete S, et al
    Adherence to cervical cancer screening among sexual and racial/ethnic minorities during the covid-19 pandemic in the United States.
    Am J Obstet Gynecol. 2025 Feb 7:S0002-9378(25)00088.
    PubMed        


    Antiviral Res

  2. SCHREIBER A, Ludwig S
    Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?
    Antiviral Res. 2025;235:106101.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  3. TORRES C, Lyden E, Gillett G, Rupp ME, et al
    Dropping the urine culture: sustained CAUTI reduction using a UTI order panel.
    Infect Control Hosp Epidemiol. 2025 Feb 13:1-7. doi: 10.1017/ice.2025.
    PubMed         Abstract available

  4. SAPIANO MRP, Dudeck MA, Patel PR, Binder AM, et al
    Patient safety as a measure of resilience in US hospitals: central line-associated bloodstream infections, July 2020 through June 2021.
    Infect Control Hosp Epidemiol. 2025 Feb 14:1-7. doi: 10.1017/ice.2024.
    PubMed         Abstract available


    Int J Infect Dis

  5. ZAMPIERI F, Michieletto F, Zanatta A
    Rise and fall of the Myth of the Good Pathogen in Evolutionary Biology and Medicine.
    Int J Infect Dis. 2025 Feb 5:107836. doi: 10.1016/j.ijid.2025.107836.
    PubMed         Abstract available

  6. LESLIE A, Chapman SA, Tessier KM, Tignanelli C, et al
    Beyond the Guidelines: Original Research on Real-World Outcomes of Anticoagulation and Corticosteroid in COVID-19.
    Int J Infect Dis. 2025 Feb 8:107834. doi: 10.1016/j.ijid.2025.107834.
    PubMed         Abstract available

  7. SHINZATO A, Hibiya K, Nishiyama N, Ikemiyagi N, et al
    Unseasonal respiratory syncytial virus epidemics during the COVID-19 pandemic: relationship between climatic factors and epidemic strain switching.
    Int J Infect Dis. 2025 Feb 8:107833. doi: 10.1016/j.ijid.2025.107833.
    PubMed         Abstract available


    Intensive Care Med

  8. ROWLAND A, Boulanger C, Dalton L
    Supporting the bereaved child in the adult ICU: a narrative review.
    Intensive Care Med. 2025 Feb 12. doi: 10.1007/s00134-025-07813.
    PubMed         Abstract available


    J Infect

  9. NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al
    Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
    J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436.
    PubMed         Abstract available


    J Med Virol

  10. HIKMAT H, Le Targa L, Boschi C, Py J, et al
    Five-Year (2017-2022) Evolutionary Dynamics of Human Coronavirus HKU1 in Southern France With Emergence of Viruses Harboring Spike H512R Substitution.
    J Med Virol. 2025;97:e70217.
    PubMed         Abstract available

  11. MAO T, Zhang P, Jiang S, Li D, et al
    Oral Ad5 Vector-Based SARS-CoV-2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice.
    J Med Virol. 2025;97:e70236.
    PubMed         Abstract available

  12. KALO E, Basyouni Z, Katz GM, Karkvandi V, et al
    Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia.
    J Med Virol. 2025;97:e70235.
    PubMed         Abstract available

  13. BERGNA A, Lai A, Sagradi F, Menzo S, et al
    Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era.
    J Med Virol. 2025;97:e70215.
    PubMed         Abstract available

  14. ZHAO M, Lei L, Jiang Y, Tian Y, et al
    Unveiling the Threat of Disease X: Preparing for the Next Global Pandemic.
    J Med Virol. 2025;97:e70227.
    PubMed         Abstract available

  15. YE J, Zhang R, Zhou J, Xu T, et al
    Systematic Reevaluation of Repurposed Drugs Against the Main Protease of SARS-CoV-2 via Combined Experiments.
    J Med Virol. 2025;97:e70229.
    PubMed         Abstract available

  16. MUKHOPADHYAY R, Lambisia AW, Hoang JP, Ravenhill BJ, et al
    Adenovirus-Specific T Cells in Adults Are Frequent, Cross-Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus-Vectored Vaccines.
    J Med Virol. 2025;97:e70222.
    PubMed         Abstract available

  17. TORRES AR, Gaio V, Melo A, Lanca M, et al
    RSV-Bacterial Co-Infection Is Associated With Increased Illness Severity in Hospitalized Children - Results From a Prospective Sentinel Surveillance Study.
    J Med Virol. 2025;97:e70209.
    PubMed         Abstract available

  18. WANG S, Sun J, Hu Y, Zhang W, et al
    Clinical and Multiorgan Proteomics Characteristics of the Diverse Fatal Phase in Super Elderly Patients With SARS-CoV-2 Infection: A Descriptive Study.
    J Med Virol. 2025;97:e70207.
    PubMed         Abstract available


    J Virol

  19. CAO X, Liu Y, Tong W, Qin W, et al
    POLM inhibits porcine epidemic diarrhea virus replication by degrading multiple viral structural proteins.
    J Virol. 2025 Feb 10:e0227824. doi: 10.1128/jvi.02278.
    PubMed         Abstract available

  20. FURUSAWA Y, Kiso M, Uraki R, Sakai-Tagawa Y, et al
    Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures.
    J Virol. 2025 Feb 12:e0221724. doi: 10.1128/jvi.02217.
    PubMed         Abstract available

  21. ZHU H, Lou J, Yang Z, Bai J, et al
    STT3B promotes porcine epidemic diarrhea virus replication by regulating N-glycosylation of PEDV S protein.
    J Virol. 2025 Feb 13:e0001825. doi: 10.1128/jvi.00018.
    PubMed         Abstract available

  22. MA R, Zhang X, Li R, Dong X, et al
    PLSCR1 suppresses SARS-CoV-2 infection by downregulating cell surface ACE2.
    J Virol. 2025 Feb 13:e0208524. doi: 10.1128/jvi.02085.
    PubMed         Abstract available


    Lancet

  23. WONG WC, Lin V, Fang X, Kidd M, et al
    The Lancet Commission on Transforming Primary Health Care in the Post-COVID-19 Era.
    Lancet. 2025 Feb 10:S0140-6736(25)00198-9. doi: 10.1016/S0140-6736(25)00198.
    PubMed        


    Lancet Infect Dis

  24. PROAL AD, Aleman S, Bomsel M, Brodin P, et al
    Targeting the SARS-CoV-2 reservoir in long COVID.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(24)00769.
    PubMed         Abstract available

  25. CHEN L, Kaku Y, Okumura K, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 LP.8.1 variant.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(25)00079.
    PubMed        


    N Engl J Med

  26. FURIE RA, Rovin BH, Garg JP, Santiago MB, et al
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965.
    PubMed         Abstract available

  27. WANG JJ, Warkentin TE, Schonborn L, Wheeler MB, et al
    VITT-like Monoclonal Gammopathy of Thrombotic Significance.
    N Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMoa2415930.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Feb. 16 '25)

 


    Am J Med

  1. SEELEY MC, Gallagher C, Ong E, Langdon A, et al
    High Incidence of Autonomic Dysfunction and Postural Orthostatic Tachycardia Syndrome in Patients with Long COVID: Implications for Management and Health Care Planning.
    Am J Med. 2025;138:354-361.
    PubMed         Abstract available

  2. MCLAUGHLIN M, Cerexhe L, Macdonald E, Ingram J, et al
    A Cross-Sectional Study of Symptom Prevalence, Frequency, Severity, and Impact of Long COVID in Scotland: Part II.
    Am J Med. 2025;138:330-336.
    PubMed         Abstract available

  3. LAU B, Wentz E, Ni Z, Yenokyan K, et al
    Physical Health and Mental Fatigue Disability Associated with Long COVID: Baseline Results from a US Nationwide Cohort.
    Am J Med. 2025;138:287-297.
    PubMed         Abstract available

  4. MCLAUGHLIN M, Sanal-Hayes NEM, Hayes LD, Berry EC, et al
    People with Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Exhibit Similarly Impaired Vascular Function.
    Am J Med. 2025;138:560-566.
    PubMed         Abstract available

  5. ZHENG C, Huang WY, Sun FH, Wong MC, et al
    Association of Sedentary Lifestyle with Risk of Acute and Post-Acute COVID-19 Sequelae: A Retrospective Cohort Study.
    Am J Med. 2025;138:298-307.
    PubMed         Abstract available

  6. LEE JS, Choi Y, Joung JY, Son CG, et al
    Clinical and Laboratory Characteristics of Fatigue-Dominant Long-COVID Subjects: A Cross-Sectional Study.
    Am J Med. 2025;138:346-353.
    PubMed         Abstract available

  7. BONNER-JACKSON A, Vangal R, Li Y, Thompson N, et al
    Factors Associated with Cognitive Impairment in Patients with Persisting Sequelae of COVID-19.
    Am J Med. 2025;138:337-345.
    PubMed         Abstract available

  8. HEJAZIAN SS, Sadr AV, Shahjouei S, Vemuri A, et al
    Prevalence and Determinants of Long-Term Post-COVID Conditions in the United States: 2022 Behavioral Risk Factor Surveillance System.
    Am J Med. 2025;138:513-523.
    PubMed         Abstract available

  9. ASHIQUE S, Mishra N, Garg A, Garg S, et al
    A Critical Review on the Long-term COVID-19 Impacts on Patients with Diabetes.
    Am J Med. 2024 Mar 12:S0002-9343(24)00133-5. doi: 10.1016/j.amjmed.2024.
    PubMed         Abstract available

  10. HOWICK V JF, Saric P, Elwazir M, Newman DB, et al
    A Pragmatic Study of Cardiovascular Disease During Long-Term COVID-19.
    Am J Med. 2024 Mar 26:S0002-9343(24)00162-1. doi: 10.1016/j.amjmed.2024.
    PubMed         Abstract available

  11. BENITO-LEON J, Lapena J, Garcia-Vasco L, Cuevas C, et al
    Exploring Cognitive Dysfunction in Long COVID Patients: Eye Movement Abnormalities and Frontal-Subcortical Circuits Implications via Eye-Tracking and Machine Learning.
    Am J Med. 2025;138:550-559.
    PubMed         Abstract available

  12. THAPALIYA K, Marshall-Gradisnik S, Eaton-Fitch N, Eftekhari Z, et al
    Imbalanced Brain Neurochemicals in long COVID and ME/CFS: A Preliminary Study using MRI.
    Am J Med. 2024 Apr 6:S0002-9343(24)00216-X. doi: 10.1016/j.amjmed.2024.
    PubMed         Abstract available

  13. PALAU P, Calvo B, Sastre C, Dominguez E, et al
    Unraveling the Mechanisms Behind Exercise Intolerance and Recovery in Long COVID.
    Am J Med. 2025;138:362-367.
    PubMed         Abstract available

  14. VELASQUEZ GARCIA HA, Wong S, Jeong D, Binka M, et al
    Risk of major adverse cardiovascular events after SARS-CoV-2 infection in British Columbia: a population-based study.
    Am J Med. 2024 Apr 24:S0002-9343(24)00237-7. doi: 10.1016/j.amjmed.2024.
    PubMed         Abstract available

  15. PAN D, Diaz JL, Weidman K, Graham J, et al
    Social Networks as a Key Health Determinant in Acute Illness Recovery: A Lesson from the COVID-19 Pandemic.
    Am J Med. 2025;138:541-549.
    PubMed         Abstract available

  16. DUNN J, Davis BR, Matarazzo A, Willett Y, et al
    New Clinical and Public Health Challenges in Vaccinations in US Adults.
    Am J Med. 2025;138:185-189.
    PubMed         Abstract available

  17. ULVI SAYGI AYVACI M, Jacobi VS, Ryu Y, Gundreddy SPS, et al
    Clinically Guided Adaptive Machine Learning Update Strategies for Predicting Severe COVID-19 Outcomes.
    Am J Med. 2025;138:228-235.
    PubMed         Abstract available


    Antimicrob Agents Chemother

  18. RODRIGUEZ L, Lee HW, Li J, Martin R, et al
    SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.
    Antimicrob Agents Chemother. 2025;69:e0123824.
    PubMed         Abstract available


    Antiviral Res

  19. TIETJEN I, Kwan DC, Petrich A, Zell R, et al
    Antiviral Mechanisms and Preclinical Evaluation of Amantadine Analogs that Continue to Inhibit Influenza A Viruses with M2(S31N)-Based Drug Resistance.
    Antiviral Res. 2025 Feb 11:106104. doi: 10.1016/j.antiviral.2025.106104.
    PubMed         Abstract available


    Epidemiol Infect

  20. CAMPMAN SL, Boyd A, Schinkel J, Coyer L, et al
    SARS-CoV-2 infection and vaccination status in six ethnic groups in Amsterdam, The Netherlands, May to November 2022.
    Epidemiol Infect. 2025;153:e23.
    PubMed         Abstract available


    J Epidemiol Community Health

  21. WEISS D, Lowenstein C, Sund ER, Vethe D, et al
    Diverging mental health trends in the postpandemic era: results from the HUNT Study, Norway.
    J Epidemiol Community Health. 2025;79:165-168.
    PubMed         Abstract available

  22. ISLAM Z, Yamamoto S, Inoue Y, Honda T, et al
    Impact of the COVID-19 pandemic on the incidence of cardiometabolic risk factors among workers: results from the Japan Epidemiology Collaboration on Occupational Health study.
    J Epidemiol Community Health. 2025;79:193-199.
    PubMed         Abstract available


    J Gen Virol

  23. WEBB I, Erdmann M, Milligan R, Savage M, et al
    Examining the feasibility of replacing ORF3a with fluorescent genes to construct SARS-CoV-2 reporter viruses.
    J Gen Virol. 2025;106:002072.
    PubMed         Abstract available


    J Infect Dis

  24. GUEZALA MC, Schilling MA
    One Health Networks for Infectious Diseases Surveillance and Pandemic Preparedness in Central and South America.
    J Infect Dis. 2025;231.
    PubMed         Abstract available

  25. SOTO G, Romero C, Gonzales M, La Rosa S, et al
    Influenza Virus Surveillance in Healthcare Personnel in Peru: NAMRU SOUTH Experience and Perspective.
    J Infect Dis. 2025;231.
    PubMed         Abstract available


    J Virol

  26. KOBAYASHI D, Hiono T, Arakawa H, Kaji H, et al
    Deglycosylation and truncation in the neuraminidase stalk are functionally equivalent in enhancing the pathogenicity of a high pathogenicity avian influenza virus in chickens.
    J Virol. 2025 Feb 14:e0147824. doi: 10.1128/jvi.01478.
    PubMed         Abstract available


    JAMA

  27. JOHANSEN ND, Biering-Sorensen T
    Electronic Nudges for Influenza Vaccination-Reply.
    JAMA. 2025 Feb 10. doi: 10.1001/jama.2024.26535.
    PubMed        

  28. WU PH, Ho YY, Chang CM
    Electronic Nudges for Influenza Vaccination.
    JAMA. 2025 Feb 10. doi: 10.1001/jama.2024.26532.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  29. LEONARD J, Harker EJ, Szablewski CM, Margrey SF, et al
    Notes from the Field: Seroprevalence of Highly Pathogenic Avian Influenza A(H5) Virus Infections Among Bovine Veterinary Practitioners - United States, September 2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:50-52.
    PubMed        


    PLoS Comput Biol

  30. SIMPSON J, Kasson PM
    Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses.
    PLoS Comput Biol. 2025;21:e1012812.
    PubMed         Abstract available

  31. LI W, Chen X, Liu S, Zhang C, et al
    Using a multi-strain infectious disease model with physical information neural networks to study the time dependence of SARS-CoV-2 variants of concern.
    PLoS Comput Biol. 2025;21:e1012778.
    PubMed         Abstract available


    PLoS One

  32. FARABI MNS, Mobin MA, Khan AN
    Assessing the efficacy of cash incentive policies in enhancing remittance inflows: Evidence from Bangladesh.
    PLoS One. 2025;20:e0318342.
    PubMed         Abstract available

  33. BRACKLEY D, Wells R
    The portrayal of panic-buying and stockpiling in English newspapers during Covid, a mixed-method content analysis.
    PLoS One. 2025;20:e0315142.
    PubMed         Abstract available

  34. INGLE L, Snook J, Smith L, Oliver B, et al
    Optimisation of the preparation phase for orthopaedic surgery: Study protocol for a student-led multimodal prehabilitation feasibility trial (BoneFit).
    PLoS One. 2025;20:e0314680.
    PubMed         Abstract available

  35. MERRITT BL, O'Neill DG, Brand CL, Belshaw Z, et al
    Lasting lockdown love? Problem behaviour and pandemic and non-pandemic related risk factors influencing the owner-dog relationship in a UK cohort of dogs reaching early adulthood.
    PLoS One. 2025;20:e0316166.
    PubMed         Abstract available

  36. DRYDEN-PETERSON S, Kim A, Caniglia EC, Joyce MR, et al
    Severe outcomes of COVID-19 among adults with increased risk conditions: A population-based observational study.
    PLoS One. 2025;20:e0316529.
    PubMed         Abstract available

  37. RUCHISRISAROD C, Wanthong P, Joyjinda Y, Bunprakob S, et al
    Antibodies response in symptomatic and asymptomatic SARS-CoV-2 infected persons in Thailand.
    PLoS One. 2025;20:e0308850.
    PubMed         Abstract available

  38. DUNDAR B
    A simulated annealing with graph-based search for the social-distancing problem in enclosed areas during pandemics.
    PLoS One. 2025;20:e0318380.
    PubMed         Abstract available

  39. MANZLI YS, Fakhfekh M, Bejaoui A, Alnafisah H, et al
    On the hedge and safe-haven abilities of bitcoin and gold against blue economy and green finance assets during global crises: Evidence from the DCC, ADCC and GO-GARCH models.
    PLoS One. 2025;20:e0317735.
    PubMed         Abstract available

  40. ASABA CN, Bitazar R, Labonte P, Bukong TN, et al
    Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity.
    PLoS One. 2025;20:e0309880.
    PubMed         Abstract available

  41. MAMELI C, Valsecchi C, Cereda D, Scarioni S, et al
    Type 1 diabetes incidence during COVID-19 pandemic has not been influenced by COVID-19 vaccination in northern Italy region, Lombardy.
    PLoS One. 2025;20:e0316340.
    PubMed         Abstract available

  42. OELSNER EC, Krishnaswamy A, Rustamov R, Balte PP, et al
    Classifying COVID-19 hospitalizations in epidemiology cohort studies: The C4R study.
    PLoS One. 2025;20:e0316198.
    PubMed         Abstract available

  43. LIU T, Wang H, Liu Y, Li Z, et al
    Effect of organizational change on employee innovation performance: A dual mediation model.
    PLoS One. 2025;20:e0313056.
    PubMed         Abstract available

  44. LI Y, Tian X, Sun C, Wei Y, et al
    Outcome of COVID-19 in patients with idiopathic inflammatory myopathy during the Omicron wave in China: A longitudinal observational study.
    PLoS One. 2025;20:e0317319.
    PubMed         Abstract available

  45. ZHU S, Alam A, Thornhill R, Tsehmaister-Abitbul V, et al
    Impact of the COVID-19 pandemic on outcomes of acute ischemic stroke patients treated with endovascular therapy: A multicenter Canadian study.
    PLoS One. 2025;20:e0316734.
    PubMed         Abstract available

  46. SHEARD L, Previdoli G, Burton W, Benchekroun R, et al
    Fair food futures UK: Protocol for a mixed methods study exploring what approaches adopted by community food organisations are more likely to prevent the need for emergency food in two multicultural communities in Northern and Southern England.
    PLoS One. 2025;20:e0304917.
    PubMed         Abstract available

  47. GEBRETEKLE TK, Albers C
    Modelling the impact of behavioural interventions during pandemics: A systematic review.
    PLoS One. 2025;20:e0310611.
    PubMed         Abstract available

  48. GANTENBERG JR, van Aalst R, Diakun DR, Bengtson AM, et al
    Healthcare utilization during acute medically attended episodes of respiratory syncytial virus-related lower respiratory tract infection among infants in the United States.
    PLoS One. 2025;20:e0313573.
    PubMed         Abstract available

  49. LIU Y, Yu H, He J, Li J, et al
    The recombinant spike S1 protein induces injury and inflammation in co-cultures of human alveolar epithelial cells and macrophages.
    PLoS One. 2025;20:e0318881.
    PubMed         Abstract available

  50. GARREC C, Arrindell J, Andrieu J, Desnues B, et al
    Preferential apical infection of Caco-2 intestinal cell monolayers by SARS-CoV-2 is associated with damage to cellular barrier integrity: Implications for the pathophysiology of COVID-19.
    PLoS One. 2025;20:e0313068.
    PubMed         Abstract available

  51. BARKET SE, Karim MR, Salan MSA
    Bayesian spatio-temporal disease mapping of COVID-19 cases in Bangladesh.
    PLoS One. 2025;20:e0316621.
    PubMed         Abstract available

  52. MATH S, Nga JDL, Lim HF, Amin M, et al
    Teledentistry-Dental students' preparedness and patients' experiences.
    PLoS One. 2025;20:e0318991.
    PubMed         Abstract available

  53. NDAMUKUNDA ONU, Mutuyimana MT, Umubano F, Tuyishime E, et al
    Socioeconomic and academic consequences of COVID-19 pandemic on medical students from the University of Rwanda.
    PLoS One. 2025;20:e0318066.
    PubMed         Abstract available

  54. SKAMAGKI G, Blackburn L, Biggs D, Kolitsida M, et al
    Exploring burnout, perfectionism, and moral injury among UK physiotherapists: A qualitative study on professional fulfilment and well-being.
    PLoS One. 2025;20:e0313730.
    PubMed         Abstract available

  55. GU JM, Zhang SN, Xiao SY, Jia MY, et al
    Effect of Chinese herbal medicine (CHM) as an adjunctive therapy in distinct stages of patients with COVID-19: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0318892.
    PubMed         Abstract available

  56. KNIPE D, de Ossorno Garcia S, Salhi L, Afzal N, et al
    Digital mental health service engagement changes during Covid-19 in children and young people across the UK: Presenting concerns, service activity, and access by gender, ethnicity, and deprivation.
    PLoS One. 2025;20:e0316468.
    PubMed         Abstract available

  57. ISMAIL H, Huam ZS, Yew SQ, Ahmad H, et al
    Sickness absenteeism among nurses after the COVID-19 pandemic: A study protocol.
    PLoS One. 2025;20:e0314763.
    PubMed         Abstract available

  58. GELYI EK, Azaare J, Bonso NK, Kpordoxah MR, et al
    Impact of perceived factors of coronavirus infection on COVID-19 vaccine uptake among healthcare workers in Ghana-Evidence from a cross-sectional analysis.
    PLoS One. 2025;20:e0318662.
    PubMed         Abstract available

  59. LOVEDAY EK, Welhaven H, Erdogan AE, Hain KS, et al
    Starve a cold or feed a fever? Identifying cellular metabolic changes following infection and exposure to SARS-CoV-2.
    PLoS One. 2025;20:e0305065.
    PubMed         Abstract available

  60. LIU W, Liu C, Wang D, She Y, et al
    A novel framework for modeling quarantinable disease transmission.
    PLoS One. 2025;20:e0317553.
    PubMed         Abstract available

  61. KOSTINOV M, Chuchalin A, Chebykina A, Khrapunova I, et al
    Clinical status and cytokine profiles in patients with asthma or chronic obstructive pulmonary disease vaccinated against influenza.
    PLoS One. 2025;20:e0313539.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  62. NGUYEN YTK, Zhu X, Han J, Rodriguez AJ, et al
    Structural characterization of influenza group 1 chimeric hemagglutinins as broad vaccine immunogens.
    Proc Natl Acad Sci U S A. 2025;122:e2416628122.
    PubMed         Abstract available

  63. BRENNECKE B, Civili B, Sabale PM, Barluenga S, et al
    Self-assembled proteomimetic (SAP) with antibody-like binding from short PNA-peptide conjugates.
    Proc Natl Acad Sci U S A. 2025;122:e2412850122.
    PubMed         Abstract available


    Vaccine

  64. ABBAD A, Yueh J, Yellin T, Singh G, et al
    Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.
    Vaccine. 2025;50:126825.
    PubMed         Abstract available

  65. FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al
    Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults.
    Vaccine. 2025;49:126770.
    PubMed         Abstract available

  66. O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al
    Protective efficacy of a bivalent equine influenza H3N8 virus-like particle vaccine in horses.
    Vaccine. 2025;50:126861.
    PubMed         Abstract available

  67. WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al
    Co-creation of pediatric influenza digital stories via rapid community translation.
    Vaccine. 2025;51:126866.
    PubMed         Abstract available

  68. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.
    Vaccine. 2025;51:126791.
    PubMed         Abstract available

  69. KIM SY, Song M, Kwon SL
    Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
    Vaccine. 2025;49:126852.
    PubMed         Abstract available

  70. VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al
    Evaluation of a nanoparticle influenza vaccine in the pig model.
    Vaccine. 2025;49:126844.
    PubMed         Abstract available

Saturday, February 15, 2025

#USA, #Ohio Reports First #Human Case of {#H5N1} #Birdflu (DOH)

(COLUMBUS, Ohio)— The Ohio Department of Health is reporting the state’s first probable human case of influenza A(H5), also known as Highly Pathogenic Avian Influenza (HPAI), or bird flu

An adult male Mercer County farm worker who was in contact with deceased commercial poultry was infected with the virus.

The Centers for Disease Control and Prevention considers the current risk of bird flu for the general public to be low. However, people with close and prolonged, unprotected contact with infected birds are at greater risk.


Guidance for the General Public

The risk of acquiring bird flu to the general U.S. population is low. The best way to prevent bird flu is to avoid direct contact with wild birds or sick or dead poultry or other animals.

Contact your local health department or local veterinarian for further guidance before you approach sick or dead poultry or wild birds.


*** REVISED *** 

Guidance for Those Who Work With Poultry

Commercial poultry owners should practice good biosecurity and prevent contact between their poultry and wild birds, specifically migratory waterfowl. 

Avoid handling sick birds or other animals and immediately report unusual signs of disease or unexpected deaths to Ohio Poultry Association at (614) 882-6111 or the Ohio Department of Agriculture at (614) 728-6220 or after hours at (888) 456-3405. 

According to the Ohio Department of Agriculture, best biosecurity practices for commercial poultry owners include:

•    Prevent Contact with wild birds and waterfowl. Keep birds indoors when possible. Add wildlife management practices around your farm. hpaifactsheet_wildlife-biosecurity.pdf (usda.gov)

•    Keep visitors to a minimum. Only allow those who care for your poultry to have contact with them and make sure they follow biosecurity principles.

•    Wash your hands before and after contact with live poultry. Use soap and water. If using a hand sanitizer, first remove manure, feathers, and other materials from your hands.

•    Provide disposable boot covers (preferred) and/or disinfectant footbaths for anyone having contact with your flock. If using a footbath, remove all droppings, mud or debris from boots and shoes using a long-handled brush BEFORE stepping in. Always keep it clean.

•    Establish a rodent and pest control program. Deliver, store, and maintain feed, ingredients, bedding and litter to limit exposure to and contamination from wild animals.

•    Use drinking water sourced from a contained supply (well or municipal system). Do not use surface water for drinking or cleaning. 

•    Clean and disinfect tools and equipment before moving them to a new poultry facility. Trucks, tractors, tools and equipment should be cleaned and disinfected prior to exiting the property. Do not move or reuse anything that cannot be cleaned.

•    Look for signs of illness. Monitor egg production and death loss, discoloration and/or swelling of legs, wattles and combs, labored breathing, reduced feed/water consumption.

More information about best biosecurity practices can be found on both the Ohio Department of Health (ODH) and Ohio Department of Agriculture (ODA) websites.


Background on Bird Flu Cases in Humans

Nationally, there have been 68 confirmed human cases of HPAI in 11 states since the beginning of 2024, which included one death in Louisiana. All but three of these cases involved exposures related to commercial agriculture and related operations or wild birds. In Ohio, one dairy herd and numerous poultry flocks have been infected since the outbreak began in 2022.

There are no known cases of human-to-human transmission.

“While the risk to Ohioans is low, the best way to prevent bird flu is to avoid unprotected exposures to sick or dead birds or to their environment,” said ODH Director Bruce Vanderhoff, MD, MBA. “People should avoid direct contact with poultry or wild birds and take proper precautions, including reaching out for guidance regarding personal protection and safe handling, if you must be around sick or dead birds.”


Additional Information

It is safe to eat properly cooked poultry and pasteurized dairy products. Generally, people should follow food safety practices – poultry, eggs, and beef should be cooked to a safe internal temperature to kill bacteria and viruses. The CDC's safer foods table contains a complete list of safe internal temperatures.

If people have been exposed to a sick or dead bird, they should monitor themselves for any new respiratory symptoms and contact their healthcare provider or local health department should they develop symptoms. Ohioans can report sick or dead wild birds to the Ohio Department of Natural Resources (ODNR) at 1-800-WILDLIFE and sick or dead poultry to the ODA at 614-728-6220.

More information on HPAI can be found on both the ODH and ODA websites.

Source: Department of Health, https://odh.ohio.gov/media-center/odh-news-releases/ohio-reports-first-human-case-of-bird-flu-021225

______

#USA, #Wyoming’s First #Human {#H5N1} #Birdflu Case Confirmed (DoH)

 Wyoming’s First Human Bird Flu Case Confirmed

February 14, 2025


Wyoming’s First Human Bird Flu Case Confirmed

Wyoming’s first case of H5N1 avian influenza in a human has been confirmed in a Platte County older adult, according to the Wyoming Department of Health (WDH). 

The woman represents the third confirmed hospitalization related to H5N1 in the United States.

“While this is a significant development as bird flu activity is monitored in Wyoming and across the country, it is not something we believe requires a high level of concern among most Wyoming residents,” said Dr. Alexia Harrist, state health officer and state epidemiologist with the Wyoming Department of Health.

Harrist said the woman is hospitalized in another state, has health conditions that can make people more vulnerable to illness, and was likely exposed to the virus through direct contact with an infected poultry flock at her home

H5N1 has been known to be infecting wild birds in Wyoming for some time now with the currently circulating virus spreading nationally since 2022. Infections among poultry and dairy cattle have also occurred previously in Wyoming.

“Experts continue to track the spread of H5N1 through wild birds, poultry and dairy cattle across the country. A small number of people have also been infected. Most of those confirmed cases involved on-the-job close contact with poultry or cattle and mild symptoms,” Harrist said. “Unfortunately, this patient’s experience has been much more serious.”

“We want to remind people there has been no documented human-to-human virus transmission of this virus in the United States so far,” Harrist said. “Our staff has followed up with other people who had contact with the flock and the patient, and will continue working with state and national experts to monitor the situation carefully for Wyoming.”

Harrist noted the current public health risk is low, but there are some common-sense steps people may consider to help protect themselves and their families:

-- Do not eat uncooked or undercooked food; cook poultry, eggs and other animal products to the proper temperature and avoid cross-contamination between raw and cooked food.

-- Avoid direct contact with wild birds.

-- Avoid contact with wild or domestic birds that appear ill or have died. If symptoms are observed in birds, immediately contact a veterinarian, or report sick domestic birds to the Wyoming Livestock Board at 307-777-8270.  If contact with the sick or dead birds is necessary, use of personal protection clothing and items is strongly recommended.

-- Avoid unprotected direct physical contact or close exposure with cattle and materials potentially infected or confirmed to be infected with bird flu.

-- Do not eat or drink raw milk or products made with raw milk.

-- Sick or dead wild birds may be reported to the Wyoming Game and Fish Department (WGFD) by calling 307-745-5865, reporting online at https://survey123.arcgis.com/share/7d0c547b8fa54eaca73f7eb37d06315a or contacting the nearest WGFD regional office.

The test result was confirmed this afternoon by a Centers for Disease Control and Prevention (CDC) laboratory.

More information about bird flu is available from the CDC at https://www.cdc.gov/bird-flu/index.html. More specific recommendations for people who have poultry are available from CDC at https://www.cdc.gov/bird-flu/groups/index.html.

Source: Department of Health, https://health.wyo.gov/wyomings-first-human-bird-flu-case-confirmed/

Friday, February 14, 2025

#USA, #Situation #summary of confirmed and probable #human #H5N1 #influenza virus cases since 2024 (as of Feb. 14 '25)

 


{Excerpt}

National Total Cases: 68

{Confirmed Cases}

Exposure source: Dairy Herds (Cattle)* - Poultry Farms and Culling Operations* - Other Animal Exposure† - Exposure Source Unknown‡

-- National - 41 - 23 - 1 - 3 - 68

1) California - 36 - 0 - 0 - 2 - 38

2) Colorado - 1 - 9 - 0 - 0 - 10

3) Iowa - 0 - 1 - 0 - 0 - 1

4) Louisiana - 0 - 0 - 1 - 0 - 1

5) Michigan - 2 - 0 - 0 - 0 - 2

6) Missouri - 0 - 0 - 0 - 1 - 1

7) Nevada - 1 - 0 - 0 - 0 - 1

8) Oregon - 0 - 1 - 0 - 0 - 1

9) Texas - 1 - 0 - 0 - 0 - 1

10)) Washington - 0 - 11 - 0 - 0 - 11

11) Wisconsin -  0 - 1 - 0 - 0 - 1

NOTE: One additional case was previously detected in a poultry worker in Colorado in 2022. Louisiana reported the first H5 bird flu death in the U.S.

{*} Exposure Associated with Commercial Agriculture and Related Operations
{†} Exposure was related to other animals such as backyard flocks, wild birds, or other mammals
{‡} Exposure source was not able to be identified

{Probable Cases}

Exposure source: Dairy Herds (Cattle)* - Poultry Farms and Culling Operations* - Other Animal Exposure† - Exposure Source Unknown‡

-- National - 1 - 6 - 0 - 1 - 8 {+1}

1) Arizona - 0 - 2 - 0 - 0 - 2

2) California - 1 - 0 - 0 - 0 - 1

3) Delaware - 0 - 0 - 0 - 1 - 

4) Ohio - 0 - 1 - 0 - 0 - {+1}

5) Washington - 0 - 3 - 0 - 0 - 3

(...)


_____

Deglycosylation and #truncation in the #neuraminidase #stalk are functionally equivalent in enhancing the #pathogenicity of a HPAI virus in #chickens

ABSTRACT

Influenza A viruses with fewer amino acids in the neuraminidase (NA) stalk domain are primarily isolated from chickens rather than wild ducks, indicating that a shortened NA stalk is considered an adaptation marker of avian influenza viruses (AIVs) to chickens. Experimental passages of an H7N7 nonpathogenic AIV (rgVac2-P0) in chickens resulted in a highly pathogenic variant (Vac2-P3L4) with a 34-amino-acid deletion in the NA stalk, encompassing five potential N-glycosylation sites. To investigate how amino acid truncation and deglycosylation in the NA stalk contribute to increased pathogenicity, a virus with glycosylation-deficient mutations at these sites (rgVac2-P3L4/P0NAΔGlyco) was constructed. Contrary to expectations, chickens inoculated with rgVac2-P3L4/P0NAΔGlyco exhibited variable clinical outcomes, attributed to the genetic instability of the virus. A single mutation stabilized the virus, and the mutant (rgVac2-P3L4/P0NAΔGlyco-Y65H) resulted in higher pathogenicity compared with a virus with restored glycosylation (rgVac2-P3L4/P0NA-Y65H). Glycan occupancy analysis revealed 3–4 glycans at the five potential sites. In functional analysis, glycosylation-deficient mutants, similar to the short-stalk NA virus, showed significantly reduced erythrocyte elution activity. Additionally, mutational analysis indicated variable contributions of N-glycans to elution activity across the sites. Moreover, the functionally most contributing sites of the five potential N-glycosylation motifs were consistently included in the amino acid deletions of the stalk-truncated NA in N7-subtyped field isolates, despite the varying truncation position or length. These findings suggest that the loss of glycosylation is functionally equivalent to a reduction in amino acids, and it plays a crucial role in enhancing pathogenicity in chickens and affecting NA function.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01478-24?af=R

_____

#Marburg Virus Disease–United Republic of #Tanzania

 {Excerpt}

Situation at a glance

Since the declaration of the Marburg Virus Disease (MVD) outbreak on 20 January 2025 in the United Republic of Tanzania, one additional confirmed death was reported by the Ministry of Health from the epicentre of the outbreak in Biharamulo district in Kagera region

As of 10 February 2025, a cumulative of two confirmed and eight probable cases were reported by the Ministry of Health. 

All 10 cases have died, including eight who died before the confirmation of the outbreak. 

As of 10 February 2025, all 281 contacts that were listed and under monitoring have completed the 21-day follow-up. 

The Ministry of Health developed a national response plan to guide activities. Additionally, a national rapid response team was deployed to the affected region to enhance outbreak investigation and response, with technical and operational support from WHO and health partners.


Description of the situation

Since the previous Disease Outbreak News on this outbreak was published on 14 January 2025, two confirmed cases have been reported, and efforts are ongoing to ascertain the source of infection.

As of 10 February 2025, a cumulative of 10 cases have been reported including two confirmed and eight probable cases. All cases resulted in death, including eight who died before the confirmation of the outbreak. 

The two cases confirmed since the outbreak declaration died while in isolation at a designated MVD treatment centre.  

On 28 January, a safe and dignified burial was performed for the last confirmed case. No new confirmed or probable cases have been reported following this burial.

The presumptive index case, an adult female, had symptom onset on 9 December and died on 16 December 2024.  

All 10 cases were reported from Biharamulo district in Kagera region; the median age of cases was 30 years (range: 1 to 75 years) and the majority of cases (70%, 7) were females. 

Cumulatively, 90 suspected cases were reported between 20 January and 10 February, all of which tested negative for MVD.

As of 10 February 2025, all 281 contacts that were listed have completed 21 days of follow-up.

The first MVD outbreak in Tanzania was reported in March 2023 in Bukoba district in Kagera region, and zoonotic reservoirs, such as fruit bats, remain endemic to the area. The outbreak in March 2023 lasted for nearly two months with nine cases including six deaths.


Epidemiology

MVD is a highly virulent disease that can cause severe disease and is clinically similar to Ebola disease (EBOD).  

EBOD and MVD are caused by orthoebolaviruses and orthomarburgviruses respectively; both are members of the Filoviridae family (filovirus). 

People become infected after prolonged exposure to mines or caves inhabited by Rousettus fruit bat colonies, a type of fruit bat, that can carry the Marburg virus.  

Marburg virus then spreads between people via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids. 

Health workers have previously been infected while treating patients with suspected or confirmed MVD. 

Burial ceremonies that involve direct contact with the body of the deceased can also contribute to the transmission of Marburg virus.

The incubation period varies from two to 21 days. Illness caused by Marburg virus begins abruptly, with high fever, severe headache and severe malaise. Severe watery diarrhoea, abdominal pain and cramping, nausea and vomiting can begin on the third day. Although not all cases present with haemorrhagic signs, severe haemorrhagic manifestations may appear between five and seven days from symptoms onset, and fatal cases usually have some form of bleeding, often from multiple areas of the body. In fatal cases, death occurs most often between eight and nine days after symptom onset, usually preceded by severe blood loss and shock. 

There is currently no approved treatment or vaccine for MVD. Some candidate vaccines and therapeutics are currently under investigation.

Eighteen outbreaks of MVD have previously been reported globally. The most recent outbreak was reported from Rwanda between September and December 2024. Additional countries that previously reported outbreaks of MVD in the African Region include Angola, the Democratic Republic of the Congo, Equatorial Guinea, Ghana, Guinea, Kenya, South Africa, the United Republic of Tanzania and Uganda. 


Public health response

The Ministry of Health developed a national response plan to guide response activities.

A National Incident Management System was activated to coordinate the response to the event and a national task force was activated, and meetings are held weekly. At the sub-national level, regular coordination meetings are being held in Kagera Region.

A national rapid response team was deployed to the affected region to enhance outbreak investigation and response, with technical and operational support from WHO and health partners.

WHO has deployed experts to support the MoH with partner coordination and other response activities in different pillars.

Surveillance activities continue with active case finding and contact tracing across affected areas.

The mobile laboratory deployed in Kabaile continues to support the testing of suspect cases for rapid turnaround time, and samples are referred to the central public health laboratory in Dar es Salaam for additional tests. Additionally, genomic sequencing was conducted on the two positive samples.

Screening of travellers departing from Kagera Region continues at key points of entry and exit, including Bukoba airport.

Healthcare worker sensitization sessions on infection prevention and control are ongoing across Kagera and other regions.

The Marburg Treatment Unit has been upgraded with enhanced triage, patient wards, and donning and doffing areas. Public awareness campaigns, including health education, door-to-door outreach by community health workers, and public announcements in high-risk areas, are ongoing.

Cross border meetings have been convened between Tanzania, Uganda and Burundi.

WHO has procured and delivered four VHF kits to Kagera region to support the response.


WHO risk assessment

The risk of this MVD outbreak is assessed as high at the national level due to several concerning factors. The outbreak thus far involves 10 cases (eight probable and two confirmed), including 10 deaths, resulting in a CFR of 100%. One case was a healthcare worker, highlighting the risk of nosocomial transmission. The source of the outbreak is still unknown. The delayed detection and isolation of cases could lead to a missed chain of transmission.

The regional risk is considered high due to Kagera's strategic location as a transit hub, with significant cross-border movement of the population to Rwanda, Uganda, Burundi and the Democratic Republic of the Congo. This highlights the potential for spread into neighbouring countries.  MVD is not easily transmissible (i.e. in most instances, it requires contact with the body fluids of a sick patient presenting with symptoms or with surfaces contaminated with these fluids). However, it cannot be excluded that a person exposed to the virus may travel.

The global risk is currently assessed as low. There is no confirmed international spread at this stage, although there are concerns about potential risks. Kagera region of Tanzania, while not close to the country’s capital or major international airports, is well-connected through transportation networks, and has an airport that connects to Dar es Salaam for onward travel outside Tanzania by air. This highlights the need for enhanced surveillance and case management capacities at relevant points of entry and along borders, as well as close coordination with neighbouring countries to strengthen readiness capacities.

(...)

Source: World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON554

_____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater {released Feb. 14 '25}



{Excerpt}

Time Period: February 02 - February 08, 2025

-- H5 Detection: 15 sites (3.9%)

-- No Detection372 sites (96.1%)

-- No samples in last week: 63 sites

(...)



Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html

_____

My New Space

Most Popular Posts